| KAUFMAN, Matthew, Xiao-Jie YAN, Wentian LI, Emanuela M GHIA, Anton W LANGERAK, Laura Z RASSENTI, Chrysoula BELESSI, Neil E KAY, Frederic DAVI, John C BYRD, Šárka POSPÍŠILOVÁ, Jennifer R BROWN, Mark CATHERWOOD, Zadie DAVIS, David OSCIER, Marco MONTILLO, Livio TRENTIN, Richard ROSENQUIST, Paolo GHIA, Jacqueline C BARRIENTOS, Jonathan E KOLITZ, Steven L ALLEN, Kanti R RAI, Kostas STAMATOPOULOS, Thomas J KIPPS, Donna NEUBERG and Nicholas CHIORAZZI. Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia. Frontiers in Oncology. Lausanne: Frontiers Media S.A., 2022, vol. 12, July 2022, p. 1-12. ISSN 2234-943X. Available from: https://dx.doi.org/10.3389/fonc.2022.897280. |
Other formats:
BibTeX
LaTeX
RIS
@article{2239436,
author = {Kaufman, Matthew and Yan, XiaoandJie and Li, Wentian and Ghia, Emanuela M and Langerak, Anton W and Rassenti, Laura Z and Belessi, Chrysoula and Kay, Neil E and Davi, Frederic and Byrd, John C and Pospíšilová, Šárka and Brown, Jennifer R and Catherwood, Mark and Davis, Zadie and Oscier, David and Montillo, Marco and Trentin, Livio and Rosenquist, Richard and Ghia, Paolo and Barrientos, Jacqueline C and Kolitz, Jonathan E and Allen, Steven L and Rai, Kanti R and Stamatopoulos, Kostas and Kipps, Thomas J and Neuberg, Donna and Chiorazzi, Nicholas},
article_location = {Lausanne},
article_number = {July 2022},
doi = {http://dx.doi.org/10.3389/fonc.2022.897280},
keywords = {chronic lymphocytic leukemia; CLL; somatic mutations; immunoglobulin variable domain; prognosis},
language = {eng},
issn = {2234-943X},
journal = {Frontiers in Oncology},
title = {Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2022.897280/full},
volume = {12},
year = {2022}
}
TY - JOUR
ID - 2239436
AU - Kaufman, Matthew - Yan, Xiao-Jie - Li, Wentian - Ghia, Emanuela M - Langerak, Anton W - Rassenti, Laura Z - Belessi, Chrysoula - Kay, Neil E - Davi, Frederic - Byrd, John C - Pospíšilová, Šárka - Brown, Jennifer R - Catherwood, Mark - Davis, Zadie - Oscier, David - Montillo, Marco - Trentin, Livio - Rosenquist, Richard - Ghia, Paolo - Barrientos, Jacqueline C - Kolitz, Jonathan E - Allen, Steven L - Rai, Kanti R - Stamatopoulos, Kostas - Kipps, Thomas J - Neuberg, Donna - Chiorazzi, Nicholas
PY - 2022
TI - Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia
JF - Frontiers in Oncology
VL - 12
IS - July 2022
SP - 1-12
EP - 1-12
PB - Frontiers Media S.A.
SN - 2234943X
KW - chronic lymphocytic leukemia
KW - CLL
KW - somatic mutations
KW - immunoglobulin variable domain
KW - prognosis
UR - https://www.frontiersin.org/articles/10.3389/fonc.2022.897280/full
N2 - Patients with CLL with mutated IGHV genes (M-CLL) have better outcomes than patients with unmutated IGHVs (U-CLL). Since U-CLL usually express immunoglobulins (IGs) that are more autoreactive and more effectively transduce signals to leukemic B cells, B-cell receptor (BCR) signaling is likely at the heart of the worse outcomes of CLL cases without/few IGHV mutations. A corollary of this conclusion is that M-CLL follow less aggressive clinical courses because somatic IGHV mutations have altered BCR structures and no longer bind stimulatory (auto)antigens and so cannot deliver trophic signals to leukemic B cells. However, the latter assumption has not been confirmed in a large patient cohort. We tried to address the latter by measuring the relative numbers of replacement (R) mutations that lead to non-conservative amino acid changes (Rnc) to the combined numbers of conservative (Rc) and silent (S) amino acid R mutations that likely do not or cannot change amino acids, "(S+Rc) to Rnc IGHV mutation ratio". When comparing time-to-first-treatment (TTFT) of patients with (S+Rc)/Rnc <= 1 and >1, TTFTs were similar, even after matching groups for equal numbers of samples and identical numbers of mutations per sample. Thus, BCR structural change might not be the main reason for better outcomes for M-CLL. Since the total number of IGHV mutations associated better with longer TTFT, better clinical courses appear due to the biologic state of a B cell having undergone many stimulatory events leading to IGHV mutations. Analyses of larger patient cohorts will be needed to definitively answer this question.
ER -
KAUFMAN, Matthew, Xiao-Jie YAN, Wentian LI, Emanuela M GHIA, Anton W LANGERAK, Laura Z RASSENTI, Chrysoula BELESSI, Neil E KAY, Frederic DAVI, John C BYRD, Šárka POSPÍŠILOVÁ, Jennifer R BROWN, Mark CATHERWOOD, Zadie DAVIS, David OSCIER, Marco MONTILLO, Livio TRENTIN, Richard ROSENQUIST, Paolo GHIA, Jacqueline C BARRIENTOS, Jonathan E KOLITZ, Steven L ALLEN, Kanti R RAI, Kostas STAMATOPOULOS, Thomas J KIPPS, Donna NEUBERG and Nicholas CHIORAZZI. Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia. \textit{Frontiers in Oncology}. Lausanne: Frontiers Media S.A., 2022, vol.~12, July 2022, p.~1-12. ISSN~2234-943X. Available from: https://dx.doi.org/10.3389/fonc.2022.897280.
|
